Tag: Exscientia
Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor
AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 "ELUCIDATE" study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 ('617), ... Read More
AI drug discovery company Exscientia raises $60m in Series C round
Exscientia, a UK-based artificial intelligence (AI) drug discovery company, has secured $60 million in a Series C financing round led by new investor Novo Holdings, ... Read More